Navigation Links
China Medicine Corporation Awarded GSP Certification
Date:12/1/2008

GUANGZHOU, China, Dec. 1 /PRNewswire-Asia/ -- China Medicine Corporation (OTC Bulletin Board: CHME) ("China Medicine" or "the Company"), a leading developer and distributor of prescription and over the counter pharmaceuticals, traditional Chinese medicines (TCM), nutritional and dietary supplements, and medical devices and medical formulations today announced that the Company was awarded GSP (Good Supply Practice for Pharmaceutical Products) certification from the Guangdong Food and Drug Administration (Guangdong FDA).

The GSP certification is given to pharmaceutical distributors that meet with the designated quality control systems required by the Guangdong FDA, which evaluates the management of employees, facility, inventory, sales and distribution systems, as well as product management systems. A stringent quality control system is required by the Chinese government to protect the integrity of the pharmaceutical industry in China as distributors are mandated to be GSP certified in order to engage in the pharmaceutical distribution business in China.

In conjunction with China Medicine's success in obtaining the GSP certification, the Company will also be considered by the Guangdong FDA to include dentistry medical devices and instruments, peptide praeparatum and protein anabolica in its distribution product offering. The Company expects to receive the official approval in approximately 7 days for the aforementioned products.

"We are honored to have received the GSP certification and we will continue to promote and improve our quality control system to ensure the safety of the pharmaceutical products we distribute to the public," said Mr. Senshan Yang, Chairman and CEO of China Medicine Corporation. "Recently, we moved our warehouse to one that is double the size of the previous warehouse and is well furnished with state-of-the-art equipment, which includes a refrigeration storage facility. We are confident that our continuous commitment to high-standard quality control systems will further solidify our position as a leading developer and distributor of pharmaceutical products in China."

About China Medicine Corporation

China Medicine Corporation is a leading pharmaceutical company which discovers, develops, and distributes over 2,300 pharmaceutical products in China including prescription and over the counter ("OTC") drugs, traditional Chinese medicine ("TCM") products, herbs and dietary supplements. The Company distributes the products to wholesale distributors in 28 provinces, over 300 hospitals, 500 medicine companies, and 1,788 drug stores throughout China. The Company actively develops a number of proprietary products for many uses including oncology, high blood pressure and the removal of toxins from food and animal feeds. For more information visit the Company's website at http://www.chinamedicinecorp.com .

Cautionary Statement

This press release contains forward-looking statements concerning the Company's business and products. The Company's actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, obtaining regulatory approval for new products, the expected contribution of higher margin products, government support for rural health care, competition from existing and new competitors, changes in technology, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risks factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

    For more information, please contact:

    Company Contact:
     Ms. Huizhen Yu
     Chief Financial Officer
     China Medicine Corporation
     Tel:   +1-732-438-8866
     Email: konzern08@163.com

    Investor Relations Contact:
     Mr. Crocker Coulson
     President
     CCG Investor Relations
     Tel:   +1-646-213-1915 (NY Office)
     Email: crocker.coulson@ccgir.com

'/>"/>
SOURCE China Medicine Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NSD Bio Group, LLC chosen by U.S.-China Economic & Security Review Commission for Report on Chinas High Tech Sectors
2. China Medical Technologies Completes the Development of EGFR Molecular Diagnostic Kits
3. China Sky One Medical, Inc. Obtains Production Rights for Nine New Drugs
4. China Biologic Products Reports Strong Third Quarter 2008 Results
5. NYSE Alternext US Accepts China Shenghuos Compliance Plan for Continued Listing
6. China Medical Technologies Receives SFDA Approval for Breast Cancer HER-2 FISH Probe
7. China Biologic Products Announces Third Quarter 2008 Results Conference Call
8. China-Biotics, Inc. Reports Second Quarter 2009 Financial Results
9. China Clean Energy Resumes Biodiesel Production After Temporary Halt
10. China Medicine Announces Conference Call to Discuss Third Quarter 2008 Results
11. Yongye Biotechnology to Present at Roth Capital China Comes to Vegas Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Sequenom, Inc. (NASDAQ: ... to enabling healthier lives through the development of innovative ... of the United States denied ... that the claims of Sequenom,s U.S. Patent No. 6,258,540 ... eligibility criteria established by the Supreme Court,s Mayo Collaborative ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. ... the faculty of the University of North Carolina Kenan-Flagler Business School ... entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The ... is proud to add Target to its list of well-respected retailers. This list ...
Breaking Biology Technology:
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
Breaking Biology News(10 mins):